BDBM50583519 OV-935::OV935::SOTICLESTAT::Soticlestat::TAK-935::TAK935

SMILES OC1(Cc2ccccc2)CCN(CC1)C(=O)c1cccnc1-c1ccncc1

InChI Key InChIKey=XKUZMIUSBMCVPP-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 50583519   

TargetCholesterol 24-hydroxylase(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50583519(SOTICLESTAT | Soticlestat | OV-935 | OV935 | TAK-9...)
Affinity DataIC50: 7.40nMAssay Description:Inhibition of CH24H expressing human 293-F cells for 15 minutes using [14C] cholesterol as substrate and measured after 5 hrs by trypan blue staining...More data for this Ligand-Target Pair
In DepthDetails Article
PubMed
TargetCholesterol 24-hydroxylase(Human)
Takeda Pharmaceutical

Curated by ChEMBL
LigandPNGBDBM50583519(SOTICLESTAT | Soticlestat | OV-935 | OV935 | TAK-9...)
Affinity DataIC50: 7.40nMAssay Description:Inhibition of full length N-terminal his6-tagged human CH24H (28 to 494 residues) expressed in Escherichia coli DH5alpha using [14C] cholesterol as s...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetCytochrome P450 2C8(Human)
Takeda Pharmaceutical Company

Curated by ChEMBL
LigandPNGBDBM50583519(SOTICLESTAT | Soticlestat | OV-935 | OV935 | TAK-9...)
Affinity DataIC50: 6.20E+4nMAssay Description:Inhibition of CYP2C8 (unknown origin) using amodiaquine as substrate incubated for 10 to 20 mins in presence of NADPH-generating system by LC-MS/MS a...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetCytochrome P450 2C9(Human)
Takeda Pharmaceutical Company

Curated by ChEMBL
LigandPNGBDBM50583519(SOTICLESTAT | Soticlestat | OV-935 | OV935 | TAK-9...)
Affinity DataIC50: 1.90E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin) using tolbutamide as substrate incubated for 10 to 20 mins in presence of NADPH-generating system by LC-MS/MS a...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetCytochrome P450 2D6(Human)
Takeda Pharmaceutical Company

Curated by ChEMBL
LigandPNGBDBM50583519(SOTICLESTAT | Soticlestat | OV-935 | OV935 | TAK-9...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CYP2D6 (unknown origin) using (S)-mephenytoin as substrate incubated for 10 to 20 mins in presence of NADPH-generating system by LC-MS/...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetCytochrome P450 3A4(Human)
Takeda Pharmaceutical Company

Curated by ChEMBL
LigandPNGBDBM50583519(SOTICLESTAT | Soticlestat | OV-935 | OV935 | TAK-9...)
Affinity DataIC50: 6.60E+3nMAssay Description:Inhibition of CYP3A4 (unknown origin) using testosterone as substrate incubated for 10 to 20 mins in presence of NADPH-generating system by LC-MS/MS ...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetCytochrome P450 1A2(Human)
Takeda Pharmaceutical Company

Curated by ChEMBL
LigandPNGBDBM50583519(SOTICLESTAT | Soticlestat | OV-935 | OV935 | TAK-9...)
Affinity DataIC50: 1.00E+5nMAssay Description:Inhibition of CYP1A2 (unknown origin) using phenacetin as substrate incubated for 10 to 20 mins in presence of NADPH-generating system by LC-MS/MS an...More data for this Ligand-Target Pair
In DepthDetails
PubMed
TargetCytochrome P450 2C19(Human)
Takeda Pharmaceutical Company

Curated by ChEMBL
LigandPNGBDBM50583519(SOTICLESTAT | Soticlestat | OV-935 | OV935 | TAK-9...)
Affinity DataIC50: 1.40E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin) using bufuralol as substrate incubated for 10 to 20 mins in presence of NADPH-generating system by LC-MS/MS an...More data for this Ligand-Target Pair
In DepthDetails
PubMed